The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis

被引：0
|
作者：
Tapper, Elliot B.
Hughes, Michael
Buti, Maria
Dufour, Jean-Francois
Flamm, Steven
Curry, Michael
Afdhal, Nezam H.
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)33920-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1663
引用
收藏
页码：S1161 / S1161
页数：1
相关论文
共 50 条
  • [1] THE OPTIMAL TIMING OF HEPATITIS C THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH CHILD B AND C CIRRHOSIS: A COST-EFFECTIVENESS ANALYSIS
    Tapper, E. B.
    Hughes, M.
    Buti, M.
    Dufour, J. -F.
    Flamm, S.
    Curry, M.
    Afdhal, N.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S800 - S800
  • [2] The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis
    Tapper, Elliot B.
    Hughes, Michael S.
    Buti, Maria
    Dufour, Jean-Francois
    Flamm, Steve
    Firdoos, Saima
    Curry, Michael P.
    Afdhal, Nezam H.
    TRANSPLANTATION, 2017, 101 (05) : 987 - 995
  • [3] The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities
    Cortesi, P. A.
    Belli, L. S.
    Facchetti, R.
    Mazzarelli, C.
    Perricone, G.
    De Nicola, S.
    Cesana, G.
    Duvoux, C.
    Mantovani, L. G.
    Strazzabosco, M.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 (07) : 791 - 801
  • [4] Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis
    Njei, B.
    McCarty, T. R.
    Fortune, B. E.
    Lim, J. K.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (10) : 1090 - 1101
  • [5] Therapy of hepatitis C: Cost-effectiveness analysis
    Koff, RS
    HEPATOLOGY, 1997, 26 (03) : S152 - S155
  • [6] Optimal Timing for Hepatitis C Treatment in Cirrhotic Patients Awaiting Liver Transplantation: A Cost-Effectiveness Analysis
    Njei, Basile
    McCarty, Thomas R.
    Ditah, Ivo C.
    Lim, Joseph K.
    Fortune, Brett E.
    GASTROENTEROLOGY, 2016, 150 (04) : S1037 - S1037
  • [7] Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis
    Chan, Jocelyn
    Kim, John J.
    Barrett, Brett K.
    Hamadeh, Abdullah
    Feld, Jordan J.
    Wong, William W. L.
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (02) : 260 - 267
  • [8] Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C
    Buti, M
    Casado, MA
    Fosbrook, L
    Wong, JB
    Esteban, R
    JOURNAL OF HEPATOLOGY, 2000, 33 (04) : 651 - 658
  • [9] Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis
    Kanwal, Fasiha
    Farid, Mary
    Martin, Paul
    Chen, Gary
    Gralnek, Ian M.
    Dulai, Gareth S.
    Spiegel, Brennan M. R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : 2076 - 2089
  • [10] Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis
    Kanwal, F
    Farid, M
    Martin, P
    Chen, G
    Gralnek, IM
    Dulai, GS
    Spiegel, BM
    HEPATOLOGY, 2005, 42 (04) : 351A - 351A
12345